Therachon

Therachon Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating TA-46, a Novel Investigational Therapy for the Potential Treatment of Achondroplasia

BASEL, Switzerland, February 14, 2018 – Therachon AG, a biotechnology company focused on rare genetic diseases, today announced the dosing of the first subject in its Phase 1 trial for TA-46, a soluble recombinant human fibroblast growth factor receptor 3 (FGFR3) ligand trap. TA-46 works by normalizing the overactive FGFR3 signaling pathways that underlie bone abnormalities …

Continue Reading
Limb Lengthening

Bones That Fit

Chandler Crews, born with the most common type of dwarfism, undergoes several procedures to lengthen her bones. This short documentary shows the strength and perseverance of a person who uncontrollably faced obstacles since their childhood and how they rose above through faith in self and science. Video by Carly Machen.

Continue Reading